Other Issues

CHPA President and CEO Scott Melville released the following statement today regarding this afternoon’s House Energy and Commerce (E&C) Committee passage of the Microbead-Free Waters Act of 2015.

CHPA expresses its gratitude to New Jersey's governor, senator, and assembly members for shepherding the bill through the legislature. CHPA has long supported state efforts to curb teen OTC cough medicine abuse.

CHPA released the following statement in response to an article in Pediatrics, the official journal of the American Academy of Pediatrics, which reported a decline in emergency department visits for unsupervised medication exposures in young children.

CHPA is pleased to lend its strong support for the DXM Abuse Prevention Act of 2015 (H.R. 3250), introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson (R-OH) and Doris Matsui (D-CA).

The Consumer Healthcare Products Association today issued the following statement in response to the Food and Drug Administration’s Drug Safety Communication on non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs).

Consumer Healthcare Products Association President and CEO Scott Melville released the following statement today regarding this afternoon’s hearing on microbeads legislation.